Sensus Healthcare (SRTS)
Supplies superficial-radiation systems for non-melanoma skin cancer and keloid treatment.
Something off on this page? Send us feedback.
Supplies SRT-100 systems for non-melanoma skin cancer and keloids, sold directly or through the Fair Deal revenue-share program. The business is centered on a single superficial-radiation platform and is concentrated in the United States.
Builds the SRT-100 family of low-energy X-ray superficial-radiation systems for non-melanoma skin cancers and keloids. The SRT-100+ adds treatment and dosimetry features, while SRT-100 Vision combines high-frequency ultrasound imaging with treatment planning.
Revenue comes from system sales, related services, and ancillary products, alongside Fair Deal agreements that provide a system, a radiotherapy technologist, and radiation-oncology and physicist oversight in return for a contractual share of collected reimbursement. The company operates as one business rather than several reportable segments.
Sales are concentrated in the United States and in a limited product family, while a single customer makes up a substantial share of revenue. Broad use depends on third-party coverage and reimbursement for SRT procedures.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 17, 2026 | Industrial Alliance Securities | Target | $6.50 | $5.50 | |
| Aug 14, 2026 | Lake Street | Reiterate | Buy | $4 | |
| May 8, 2026 | Industrial Alliance Securities | Target | $6.50 | ||
| Feb 17, 2026 | Maxim Group | Reiterate | Buy | $6 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $15.2M · Total debt $343.0K · Total assets $41.3M · Shareholders' equity $36.9M
- Revenue
- $2.3M
- Operating income
- −$3.2M
- Net income
- −$8.7M
No dividends on record.
| Institutions43 holders · as of Mar 31, 2026 | 23.99% | 3.95M shares | |
| Insiders9 holders · as of Aug 31, 2026 | 18.90% | 3.11M shares | |
| Otherremainder | 57.11% | 9.40M shares |
16.46M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Edwin L. Solot, Jr.Insider | 7.56% | 1.25M | 13Gfiled Feb 7, 2025 ↗ |
Joseph C. SardanoInsiderdirector, officer: CHIEF EXECUTIVE OFFICER | 7.41% | 1.22M | Form 4filed Aug 24, 2026 ↗ |
Pacific Ridge Capital Partners, LLCInstitution | 4.84% | 796,072 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 3.94% | 648,225 | 13Fas of Mar 31, 2026 |
Dimensional Fund Advisors LPInstitution | 2.35% | 387,392 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 31, 2026 | Eric Sachetta | director | +27,304 | $3.54 |
| Aug 28, 2026 | Eric Sachetta | director | +37,537 | $3.44 |
| Aug 27, 2026 | Eric Sachetta | director | +10,925 | $3.18 |
| Aug 26, 2026 | Eric Sachetta | director | +9,708 | $3.29 |
| Aug 24, 2026 | Eric Sachetta | director | +34,697 | $3.25 |
